deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT01880359

AF CRT +/- Nimorazole in HNSCC

A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck.

Sponsor: Danish Head and Neck Cancer Group

Conditions Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers
Interventions Cisplatin Nimorazole Placebo Radiotherapy
Updated 16 times since 2017 Last updated: May 9, 2022 Started: Jul 25, 2014 Primary completion: Sep 6, 2019 Completion: Jan 9, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers, this trial is ongoing. The trial is conducted by Danish Head and Neck Cancer Group and has accumulated 16 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Mar 2019 · 7 months · monthly snapshot~Mar 2019 – ~Sep 2019 · 6 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Jun 2024 · 24 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jun 2024 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Jun 2022 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 11 earlier versions

  1. Jan 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Aug 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  10. Jul 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Danish Head and Neck Cancer Group
  • European Organisation for Research and Treatment of Cancer - EORTC
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Berlin, Germany , Brisbane, Australia , Brussels, Belgium , Dijon, France , Gdansk, Poland , Geneva, Switzerland , Leuven, Belgium , München, Germany , Nijmegen, Netherlands and 7 more locations